AUPH: חוב לטווח קצר של החברה Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (AUPH) is implementing automation in drug packaging and testing robots for protein analysis. The delivery of treatments for autoimmune pathologies is ensured by strict control of transportation conditions, and the indicator is 0.02. The price trajectory shown below confirms that the business relies on an asset-light model, outsourcing the production of nephritis treatments to Lonza plants, which makes the company dependent on external suppliers.

The Aurinia Pharmaceuticals (AUPH) business model relies on the high margins of its exclusive kidney treatment drug. By analyzing short-term borrowing levels on GURU.Markets, an investor assesses the volume of liabilities maturing within one year. This metric measures liquidity and the company's ability to service urgent loans without disrupting operational activities. An increase in this indicator may signal preparations for scaling distribution. A stable debt balance confirms the financial stability of the asset.